| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/07/2004 | US6787548 Cardiovascular insufficiency and erectile dysfunction; 3-(4-(3-chloro-4-hydroxybenzylamino) benzo(4,5)thieno(2,3-d)pyrimidin-2-yl)propionic acid |
| 09/07/2004 | US6787542 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| 09/07/2004 | US6787540 Compounds useful as reversible inhibitors of cysteine proteases |
| 09/07/2004 | US6787539 2,4,5,-trisubstituted pyrimidine derivatives |
| 09/07/2004 | US6787536 Hydroxamic acid derivatives |
| 09/07/2004 | US6787534 Sulfonamide-containing heterocyclic compounds |
| 09/07/2004 | US6787521 Skin disorders; kidney and liver disorders |
| 09/07/2004 | US6787519 Methods of treating disorders related to apoE |
| 09/07/2004 | US6787326 For destruction in normoxic but not hypoxic cells; promotes angiogenesis and/or cellular survival; fusion proteins |
| 09/07/2004 | US6787309 Nucleotide sequences coding cardiovascular protein for use in the diagnosis and treatment chromosomal disorder |
| 09/07/2004 | US6787141 Peptide having for fibrinogen fragment E activity, analogs, antibodies and uses thereof |
| 09/02/2004 | WO2004074831A1 Treatment of hypertension |
| 09/02/2004 | WO2004074494A1 Method of treating ischemic disease |
| 09/02/2004 | WO2004074312A2 Tryptophyllin peptides and uses thereof |
| 09/02/2004 | WO2004074297A1 Aminophosphonic acid derivatives, addition salts thereof and s1p receptor modulators |
| 09/02/2004 | WO2004074258A1 Novel sulphated imidazole derivatives, method for production thereof, novel intermediates obtained, application thereof as medicaments and pharmaceutical compositions comprising the above |
| 09/02/2004 | WO2004074239A1 Acylated aminopropanediols and analogues and therapeutic uses thereof |
| 09/02/2004 | WO2004074236A1 Novel transcriptional factor, process for producing the same and use thereof |
| 09/02/2004 | WO2004073740A1 Regulator of interstitial angiotensin ii hyperproduction and preventive or remedy for the onset of arteriosclerosis, heart and brain vascular diseases and/or diabetic complications |
| 09/02/2004 | WO2004073733A1 Interleukin 6 production inhibitor |
| 09/02/2004 | WO2004073723A1 Medical drug containing fine particle of noble metal |
| 09/02/2004 | WO2004073718A1 Therapeutic agent for hemorrhoidal disease |
| 09/02/2004 | WO2004073717A1 Blood-vessel-growth promoter |
| 09/02/2004 | WO2004073716A1 Method for treating severe heart failure and medicament therefor |
| 09/02/2004 | WO2004073712A1 Pharmaceutical combinations comprising a nos inhibitor and an nmda receptor antagonist |
| 09/02/2004 | WO2004073701A1 Lfa-1 inhibitors and use thereof |
| 09/02/2004 | WO2004073694A1 Method to treat chronic heart failure and/or elevated cholesterol levels |
| 09/02/2004 | WO2004073613A2 A medicine and food |
| 09/02/2004 | WO2004073602A2 Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| 09/02/2004 | WO2004073593A2 Use of acylated aminopropanediols and sulphur and nitrogen analogues of same for different therapeutic applications |
| 09/02/2004 | WO2004073588A2 Diagnostics and therapeutics for diseases associated with g protein coupled receptor r35 (r35) |
| 09/02/2004 | WO2004073586A2 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor tg1019 (tg1019) |
| 09/02/2004 | WO2003084539A3 New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
| 09/02/2004 | WO2003072813A3 Single nucleotide polymorphisms predicting adverse drug reactions and medication efficacy |
| 09/02/2004 | WO2003049698A8 Substituted hydrazones as inhibitors of cyclooxygenase-2 |
| 09/02/2004 | US20040171908 Cardiac disease treatment and device |
| 09/02/2004 | US20040171907 Cardiac disease treatment and device |
| 09/02/2004 | US20040171864 Fluorinated aromatics |
| 09/02/2004 | US20040171848 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 09/02/2004 | US20040171844 Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase |
| 09/02/2004 | US20040171839 Serine protease inhibitor; therapy for thrombosis , cardiovascular disorders |
| 09/02/2004 | US20040171835 Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient |
| 09/02/2004 | US20040171832 Novel sulfonate substituted pyrazol pyridine derivatives |
| 09/02/2004 | US20040171830 Carboline derivatives as pdev inhibitors |
| 09/02/2004 | US20040171804 for drug screening cancer, osteoporosis, obesity, Alzheimer's disease drugs; genetic engineering; kits |
| 09/02/2004 | US20040171680 Peroxisome proliferator activated receptor alpha modulators; such as 2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionic acid |
| 09/02/2004 | US20040171679 Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| 09/02/2004 | US20040171671 Cyclic ester of 3-hydroxybutyric acid; increasing cardiac efficiency, alternative glucose energy source, free radical scavenging |
| 09/02/2004 | US20040171665 Novel polymorphic form IV and solvate; precipitation from ethyl acetate |
| 09/02/2004 | US20040171664 Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event |
| 09/02/2004 | US20040171658 Blood coagulation factor Xa inhibition; such as 2-O-(3'-amidinobenzyl)-5-O-(3''-amidinophenyl)-1,4:3,6-dianhydrosorbitol |
| 09/02/2004 | US20040171643 Acylaminothiazole derivatives, their preparation and therapeutic use |
| 09/02/2004 | US20040171641 Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) |
| 09/02/2004 | US20040171639 Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists |
| 09/02/2004 | US20040171627 quinazolinone derivatives, especially halofuginone, can also inhibit the pathophysiological processes of renal fibrosis in vivo, including the effect on both the glomeruli and the tubuli interstitial compartments |
| 09/02/2004 | US20040171617 treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer |
| 09/02/2004 | US20040171616 preventing and treating thrombotic conditions, such as coronary artery disease, cerebrovascular disease, and other coagulation related disorders |
| 09/02/2004 | US20040171607 Chemical compounds |
| 09/02/2004 | US20040171605 Benzoxazepines derivatives and their use as ampa receptor stimulators |
| 09/02/2004 | US20040171594 Use of bis-acid(5-androsten-17-one-3beta-hydroxyl)diester for manufacture pharmaceuticals |
| 09/02/2004 | US20040171592 reduced gastric effects; salicylic acid derivatives |
| 09/02/2004 | US20040171589 Differential delivery of nitric oxide |
| 09/02/2004 | US20040171584 formulations of ANGIOTENSIN II AT1 receptors antagonists, using the cyclodextrins or their derivatives, lipossomes and the biodegradable polymers; increasing the bio-availability of losartan |
| 09/02/2004 | US20040171581 Polysaccharidic esters of retinoic acid |
| 09/02/2004 | US20040171557 treating or educating said cells ex vivo in the presence of: intermediary metabolite; antigens or epitopes associated with said disease, or the immune-mediated inflammatory response; re-administering to said subject said treated or educated cells |
| 09/02/2004 | US20040171549 Method of inhibiting angiogenesis or invasion or formation of metastases |
| 09/02/2004 | US20040171538 Anticoagulants and their uses |
| 09/02/2004 | US20040171530 Polypeptides containing cysteine and tryptophan |
| 09/02/2004 | US20040171528 Raise intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171527 Regulation of immune responses by manipulation of intermediary metabolite levels |
| 09/02/2004 | US20040171526 Raise intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171522 Raise the intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171520 Melanocortin receptor-specific peptidomimetics |
| 09/02/2004 | US20040171123 fusion protein of an antibody that binds to human epidermal growth factor receptor-2 (HER2) and albumin with long shelf-life; stabilizing therapeutic proteins such as antibodies by conjugating them to albumin |
| 09/02/2004 | US20040171110 Novel member of the lysyl oxidase gene family |
| 09/02/2004 | US20040171080 Method of assaying for agonists or antagonist of dynorphin a binding to the mas receptor |
| 09/02/2004 | US20040171018 Mouse farnesoid x receptor sequences for use in comparative pharmacology |
| 09/02/2004 | US20040171012 Nucleic acid-associated proteins |
| 09/02/2004 | US20040170999 Nuclear hormone receptor ligand binding domain |
| 09/02/2004 | US20040170997 used in drug screening for preventing or treating diseases associated with abnormalities in intracellular signal transduction; genetic engineering |
| 09/02/2004 | US20040170995 for drug screening in vitro for mitogen-activated protein kinase-activated protein kinase-2 modulators using expression libraries; genetic engineering; kits |
| 09/02/2004 | US20040170993 Methods for diagnosing and treating heart disease |
| 09/02/2004 | US20040170969 GRF2 binding proteins and applications thereof |
| 09/02/2004 | US20040170712 Applying a Jojoba oil extruded from Jojoba seeds |
| 09/02/2004 | US20040170711 Medical effect of Jojoba oil in the treatment of anal diseases |
| 09/02/2004 | US20040170710 Treating vaginal diseases by applying Jojoba oil extruded from Jojoba seeds |
| 09/02/2004 | US20040170704 Process for the manufacture of a herbal composition |
| 09/02/2004 | US20040170684 For therapy of incontinence |
| 09/02/2004 | US20040170624 active principle, especially the humanized monoclonal antibody JAQ1, that induces irreversible inactivation or degradation of the collagen receptor on thrombocytes; diagnostic agent for the determination of the expression rate of the collagen receptor GPVI |
| 09/02/2004 | US20040170620 Selected antibody compositions for binding to aminophospholipids |
| 09/02/2004 | US20040170618 antagonists bind to a recognized target (e.g., a receptor); the enzyme component of the chimera then degrades the target resulting in a reduction of activity of the target and release of the chimeric molecule, which is then free to attack and degrade another target molecule. |
| 09/02/2004 | CA2833559A1 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 09/02/2004 | CA2518313A1 Medicament comprising noble metal fineparticles |
| 09/02/2004 | CA2516486A1 Method of treating ischemic disease |
| 09/02/2004 | CA2516450A1 Method to treat chronic heart failure and/or elevated cholesterol levels |
| 09/02/2004 | CA2515680A1 Acylated aminopropanediols and analogues and therapeutic uses thereof |
| 09/02/2004 | CA2515567A1 Pharmaceutical combinations comprising a nos inhibitor and an nmda receptor antagonist |
| 09/02/2004 | CA2515480A1 Use of acylated aminopropanediols and sulphur and nitrogen analogues of same for different therapeutic applications |
| 09/02/2004 | CA2515251A1 Blood-vessel-growth promoter |
| 09/02/2004 | CA2493475A1 Method for treating severe heart failure and medicament therefor |